• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy

    2022-11-21 09:10:16siQiLiYangYangLinSenYe
    World Journal of Gastroenterology 2022年42期

    si-Qi Li, Yang Yang,Lin-Sen Ye

    Abstract The disease burden related to hepatocellular carcinoma (HCC) is increasing. Most HCC patients are diagnosed at the advanced stage and multikinase inhibitors have been the only treatment choice for them. Recently, the approval of immune checkpoint inhibitors (ICIs) has provided a new therapeutic strategy for HCC. It is noteworthy that the positive outcomes of the phase III clinical trial IMBrave150[atezolizumab (anti-programmed cell death ligand 1 antibody) combined with bevacizumab (anti-vascular endothelial growth factor monoclonal antibody)],showed that overall survival and progression-free survival were significantly better with sorafenib. This combination therapy has become the new standard therapy for advanced HCC and has also attracted more attention in the treatment of HCC with anti-angiogenesis-immune combination therapy. Currently, the synergistic antitumor efficacy of this combination has been shown in many preclinical and clinical studies. In this review, we discuss the mechanism and clinical application of anti-angiogenics and immunotherapy in HCC, outline the relevant mechanism and rationality of the combined application of antiangiogenics and ICIs, and point out the existing challenges of the combination therapy.

    Key Words: Anti-angiogenesis; Immunotherapy; Combination therapy; Vascular endothelial growth factor; Immune checkpoint blockade; Hepatocellular carcinoma

    INTRODUCTION

    According to the statistics from the National Cancer Center of China, the incidence and mortality of hepatocellular carcinoma (HCC) are increasing annually[1]. The World Health Organization (WHO)estimates that, from 2015 to 2030, approximately 10 million people in China will die due to liver cirrhosis and HCC. Although early-stage disease can be cured by surgical removed, transplantation, or interventional therapy, most patients have unresectable disease at the time of diagnosis[2], and current treatments are insufficient to prevent the high metastasis and recurrence rates after HCC treatment.

    Currently, immunotherapy is receiving a great deal of attention in the treatment of tumors. Among the immunotherapy options, immune checkpoint blockade (ICB)-based immunotherapy which reactivates dysfunctional or exhausted T cells has shown excellent efficacy in a variety of solid cancers and hematological tumors[3-7]. However, 50%-80% of cancer patients still do not benefit from immunotherapy, and many of them suffer serious adverse events (AEs) during treatment[8]. In fact, there is still no clear mechanism to explain the tolerance of many cancers to immune checkpoint inhibitors (ICIs).HCC is a solid tumor with complex pathophysiological barriers. It is difficult for external lymphocytes to penetrate and infiltrate into tumor tissue. In addition, the rapidly growing tumor cells release immunosuppressive factors, which result in HCC forming an immunosuppressive immune microenvironment, which greatly limits the efficacy of immunotherapy[9]. In addition, the rapidly growing tumor cells release several factors, which result in HCC forming an immunosuppressive immune microenvironment, that greatly limits the efficacy of immunotherapy[10,11]. Therefore, normalizing tumor vasculature and improving the tumor hypoxic microenvironment is expected to reverse the immunosuppressive microenvironment of HCC and promote HCC immunotherapy.

    The TME is mainly composed of the vasculature, resident or infiltrating immune cells and various stromal cells. Previous studies have shown that abnormal tumor vasculature promotes the formation of an immunosuppressive TME[11]. Therefore, therapies that promote normalization of the vasculature are of great significance for enhancing immunotherapy of HCC. This review outlines measures to normalize the vasculature of HCC and the common immunotherapy regimens for HCC, and further describes and discusses how to normalize the tumor vasculature to improve the efficacy of immunotherapy in HCC(especially ICB). Additionally, we discuss the challenges associated with emerging combinations of vascular normalization therapy and immunotherapy for HCC.

    ABNORMAL ANGIOGENESIS AND VASCULAR NORMALIZATION MEASURES FOR HCC

    Abnormal angiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor

    The excessive growth and abnormal proliferation of tumor cells depend on rapid tumor angiogenesis.Tumor angiogenesis not only provides tumor cells with oxygen, nutrients and removes waste, but also serves as a channel for metastasis of tumor cells and immune cell infiltration[12,13]. However,compared with vessels in normal tissues, tumor neo-vessels have obvious aberrations in both structure and function[11]. Leakage is one of the most notable features of tumor vessels. On the one hand, this property can lead to tumor hypoxia and decreased intra-tumoral pH by impairing perfusion, and on the other hand, leakage will increase interstitial pressure in the TME[10]. Tumor cells overcome these harsh conditions through multiple mechanisms to gain a survival advantage[11]. Abnormal vessels limit the circulation of drugs and immune cells into the tumor, thereby limiting anti-tumor activity[11]. The hypoxia and pH reduction in the tumor caused by abnormal vessels will further lead to abnormal neovascularization, forming a vicious circle.

    In the field of cancer research, most studies on angiogenesis has focused on the increased expression of angiogenesis factors [such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), angiopoietin, hepatocyte growth factor, endoglin (CD105,etc)] and decreased expression of anti-angiogenesis factors, such as angiostatin, endostatin, and thrombospondin 1, which is mainly caused by upregulation of the hypoxia-inducible factor protein.Among these, VEGF/VEGF receptor (VEGFR) axis are widely known to play a major role in vascular abnormalities and are crucial for the occurrence and progression of HCC[14-16]. The VEGF family consists of VEGFA, VEGFB, VEGFC, VEGFD and placental growth factor (PlGF) 1-4, which are involved in tumor angiogenesis (VEGFA, PlGF), maintenance of new blood vessels (VEGFB), lymph-angiogenesis and angiogenesis (VEGFC/D), vascular permeability (VEGFA/C), chemotaxis (VEGFB), migration(VEGFA, PlGF), differentiation (VEGFD) and survival (VEGFA/B/C, PlGF)[17,18]. VEGFR mainly includes VEGFR1, VEGFR2, and VEGFR3[15]. Of these, VEGFR2 is the critical receptor of this family,which is expressed on almost all endothelial cells and is activated by binding to VEGFA, VEGFC or VEGFD, and VEGFA is its major ligand[19]. This binding results in the phosphorylation cascade that triggers downstream cellular pathways, ultimately leading to endothelial cell proliferation and migration, and the formation and branching of new tumor blood vessels[19]. These neo-vessels often manifest as abnormal leaky vasculature, resulting in high interstitial pressure and severe hypoxia or necrosis in tissue regions, further promoting the malignant potential of tumor cells[20]. Previous studies have shown that circulating VEGF levels are increased in HCC, and increased VEGFA has been shown to be associated with angiogenesis in HCC[21,22]. In addition, related studies also observed a positive association between increased local and circulating VEGF and high tumor micro-vessel density with rapid disease progression and decreased survival. These findings support the application of therapies that target the VEGF/VEGFR pathway in HCC[21,22].

    Vascular normalization measures in HCC and targeting of the VEGF/VEGFR axis

    Various molecular and physical mechanisms have been reported to contribute to tumor vascular dysfunction, the most prominent of which is the imbalance of angiogenic signaling mediated by proand anti-angiogenic molecules[11,23]. In normal tissue, this balance is precisely maintained to ensure normal vascular morphology and function[24]. However, during the process of carcinogenesis, this balance usually tends to angiogenesis, and the generated neo-vessels are immature abnormal vessels without complete structure[24]. In view of the key role of the VEGF/VEGFR axis in abnormal angiogenesis of HCC, rational targeting of this axis can promote the normalization of tissue vessels and limit the occurrence and development of HCC.

    In the past few decades, the development of anti-angiogenesis therapy has mainly focused on blocking VEGF[17,18]. Several studies have also focused on blocking VEGF signaling by silencing VEGFA expression at the transcriptional and post-transcriptional levels. For example, Zouet al[25]identified emodin that could greatly increase seryl-tRNA synthetase expression in tripe-negative breast cancer (TNBC) cells, consequently reducing VEGFA transcription, and emodin potently inhibited vascular development of zebrafish and blocked tumor angiogenesis in TNBC-bearing mice, greatly improving the survival. Liet al[26] and Dinget al[27] raised that VEGF small interference RNA can precisely and efficiently silence VEGF expression and block VEGF signal pathway, leading to a significant decrease in tumor blood vessels and suppression of tumor growth and metastasis. However,these studies have only been tested in animals. Preclinical evidence suggests that monotherapy which blocks VEGF reduces micro-vessel density, inhibits tumor growth in many cancerous subcutaneous xenografts, and even inhibits tumor cell metastasis[28,29]. Ferraraet al[30] researched and developed the first anti-angiogenesis inhibitor (bevacizumab), a recombinant humanized monoclonal antibody that blocks VEGFA. Bevacizumab binds to VEGF in the bloodstream, thereby inhibiting the interaction between VEGF and VEGFR. In clinical trials of combination therapy for HCC, multiple lines of evidence suggest that bevacizumab has a potential therapeutic effect[31,32].

    On the other hand, many anti-angiogenesis therapies in HCC focus on targeting VEGFR. Multikinase inhibitors (MKIs) and monoclonal antibodies (mAbs) were developed to inhibit VEGFR and its downstream targets to inhibit endothelial cell proliferation, thereby reducing the nutrient and oxygen supply required by tumors. Currently, the VEGFR-targeted MKIs and mAbs used in advanced HCC mainly include sorafenib, regorafenib, lenvatinib, cabozantinib, and ramucirumab (Table 1).

    Sorafenib is an oral MKI that blocks VEGFR1-3, c-Kit, PDGF receptor (PDGFR)-b, and FMS-like tyrosine kinase-3 (FLT-3)[33]. The phase III clinical trial SHARP showed a 2.8-mo survival advantage for sorafenib over placebo in patients with advanced HCC. This recent study also showed that sorafenib can benefit patients with HCC regardless of etiology, and patients with hepatitis C appeared to experience greater benefit[34]. Treatment-related AEs were more common in the sorafenib group than in the placebo group (80%vs52%), and the incidence of dose reductions and interruptions was high during treatment. The MKI regorafenib also targets VEGFR, RET, c-Kit, B-Raf, FGFR1 and PDGFR[33]. It is the first therapy to demonstrate a survival benefit in advanced HCC patients who have progressed on sorafenib[35]. Fatigue, hypertension, diarrhea and hand-foot skin reactions were common AEs in the regorafenib-treated group. Other analyses showed that the survival benefit of first line sorafenib and second line regorafenib was more than 24 mo[35]. The targets of lenvatinib include VEGFR1-3, FGFR1-4,PDGFRa, RET and c-Kit. Recently, a phase III study of lenvatinibvssorafenib in patients withunresectable HCC showed that overall survival (OS) with lenvatinib was non-inferior to sorafenib[36].The most common AEs in the lenvatinib group were diarrhea, fatigue,etc[36]. It should be noted that patients with tumors with more than 50% hepatic masses or involvement of branches of the main portal vein were excluded from the trial (NCT01761266); thus, further clinical trials should be conducted.Despite this problem, lenvatinib remains the only drug in first-line clinical trials that was positive against the proven active control, sorafenib. In addition to targeting VEGFR2, c-Kit, RET, FLT-3, Tie2,and Axl, cabozantinib has the unique property of inhibiting c-Met, and its potential activity was observed in phase II trials[37]. The subsequent phase III clinical trial, which compared cabozantinib to placebo in advanced HCC, met its primary endpoint of improved OS after up to two prior treatments,one of which included sorafenib[38]. Hypertension, pneumonia were common AEs in the cabozantinib group[38]. Ramucirumab, the mAb that antagonizes VEGFR2, improved OS in a phase III study in patients with sorafenib progression or intolerance with baseline alpha-fetoprotein (AFP) ≥ 400 ng/mL[39]. Hypertension and hyponatremia were the only over grade 3 AEs in patients of the test group[39].Based on the results of the previous phase III study, patients can be selected for treatment based on baseline AFP values. A survival benefit was observed with ramucirumab in a subgroup of patients with higher baseline AFP (400 ng/mL), which is the first positive clinical trial in the biomarker-selected HCC population[39].

    Table 1 Currently approved anti-angiogenic therapy for advanced hepatocellular carcinoma

    IMMUNOTHERAPY IN HCC

    Driven by the success of ICB therapy in melanoma, ICB has been extensively studied in a variety of malignancies including HCC[40,41]. Long-term liver injury or chronic hepatitis infection often leaves the liver in a state of chronic inflammation[42]. Moderate inflammation can defend against pathogens and repair tissue damage, whereas persistent liver inflammation can disturb the microenvironment,thus favoring carcinogenesis. On the one hand, hepatic endocrine cytokines play a key role in tumorigenesis through regulating regulatory T cells (Tregs) that inhibit CD8+T cell activation[43]. It was previously reported that Tregs derived from hepatitis B virus-positive HCC tumors exhibited higher programmed cell death protein 1 (PD-1) expression and superior inhibitory capacity against CD8+T cells. On the other hand, cytotoxic immune populations frequently express markers of exhaustion such as PD-1, cytotoxic t-lymphocyte associated antigen 4 (CTLA-4) and lymphocyte activating gene 3[44].Under normal conditions, these molecules inhibit T cell activation to maintain inflammatory homeostasis, protect tissue integrity, and prevent unnecessary autoimmunity[45]. However, in tumors,expression of these markers of exhaustion is inversely correlated with their function, making them a prime target for ICBs to revitalize and restore the cytotoxic capacity of CD8+T cells[43]. At the same time, the expression of PD-1 and its ligand (PD-L1) in tumor cells is upregulated, and when it binds to PD-1 expressed by T cells activated by tumor infiltration, it induces T cell exhaustion and suppresses the anti-tumor immune activity of these immune cells, thereby enabling tumor cells to evade immunity[46].ICBs generate robust multitarget immune responses and can even induce long-lasting tumor remissions in some patients. Inhibition of the PD-1/PD-L1 interaction reverses the depleted state of these cytotoxic immune cells and reactivates their antitumor activity[46,47]. In HCC, the mAbs pembrolizumab and nivolumab that target PD-1, and nivolumab combined with ipilimumab (a mAb directed against CTLA-4), has been approved in the United States for sorafenib-treated patients, based on promising results from clinical trials[48-50]. A clinical trial confirmed the efficacy and safety of PD-1-targeting immunotherapy in HCC[51]. However, subsequent phase III trials of nivolumabvssorafenib in first-line therapy failed to meet the primary survival endpoints[50,52]. The combination of phase III nivolumab and ipilimumab is currently under evaluation (NCT04039607).

    In the current phase III clinical treatment of HCC, immune combination therapy has attracted considerable attention, especially the combination of ICIs and anti-angiogenic inhibitors (Table 2). Lenvatinib combined with pembrolizumab, bevacizumab combined with atezolizumab (PD-L1-targeting mAb)(T+A combination), and cabozantinib combined with atezolizumab have all obtained encouraging results in clinical studies[53-55]. Of these, the combination of bevacizumab and atezolizumab has been successful in phase III clinical trials of first-line treatment of HCC (IMbrave150). Compared with sorafenib, this combination improved the primary endpoints: OS and progression-free survival, and this combination was shown to be safe and improved quality of life[56]. Hypertension and proteinuria were typical side effects of bevacizumab and were the top two AEs in this test group. Upper gastrointestinal bleeding, another known side effect of bevacizumab, occurred in 7% of patients in this group, and was within the range of previous evaluations of bevacizumab AEs for the treatment of HCC[57,58]. Elevated transaminases and pruritus are common side effects of atezolizumab[32]. As this study applied the usual inclusion criteria in HCC clinical trials and included only Child-Pugh A patients, further clinical trials are pending[32].

    Angiogenesis and immune checkpoint combination blockade in HCC

    As shown above, the success of the phase III trial (IMbrave150) with the combination of atezolizumab and bevacizumab in advanced HCC is groundbreaking as it is the first treatment with a better survival rate than sorafenib since the approval of sorafenib in 2007 and is also the only successful first-line immunotherapy combination therapy for HCC in the world[32]. Antibodies targeting VEGF not only inhibit tumor growth but also reprogram the TME from immunosuppressive to immune activation[8,59]. Based on these findings, PD-1/PD-L1 inhibitors combined with VEGF/VEGFR inhibitors have attracted extensive attention in the treatment of HCC. Next, we will outline the mechanism and rationality of PD-1/PD-L1 inhibitors combined with VEGF/VEGFR inhibitor therapy, and the biomarkers of response to targeted immune combination therapy.

    Mechanism and rationality

    In the tumor area, VEGF released by hypoxic cancer cells promotes tumor cell growth and metastasis by angiogenesis[8]. On the other hand, VEGF can also promote the malignant progression of tumors by affecting the TME (Figure 1). The tumor immune cycle mainly includes seven steps, the release of tumor antigens, the uptake and presentation of tumor antigens by dendritic cells (DCs), the initiation and activation of T cells, the migration of T cells to tumors, the invasion of T cells against tumors, the recognition of tumor cells by T cells, and the attack of tumor cells by T cells[60]. VEGF is involved in almost every step of the tumor immune cycle and finally promotes tumor immune escape[61-64]. VEGF enhances the mobilization and proliferation of immunosuppressive cells, including Tregs, tumorassociated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs)etc, enhances the release of immunosuppressive cytokines[8,59], and promotes M1-TAMs to M2 type polarization. In addition, Tregs and TAMs release immunosuppressive factors, such as VEGF and angiopoietin 2, which form positive feedback to further promote tumor progression[65]. Furthermore, VEGF inhibits the maturation and antigen presentation of DCs. Thus, even in the presence of neoantigens, VEGF can reduce the proliferation and activation of naive CD8+ cells by inhibiting DCs[65]. VEGF prevents antigen activated CD8+ T cells from infiltrating tumor tissue by promoting the formation of abnormal tumor vessels. In addition, VEGF forms an immunosuppressive TME that inhibits the function of T cells in tumors during the effector phase of the immune response[65]. Therefore, inhibition of VEGF/VEGFR interaction not only normalizes vessels but also enhances antitumor immunity.

    Previous studies have shown that inhibition of VEGF/VEGFR can enhance antitumor immunity.Gabrilovichet al[63] found that the targeted drugs which inhibit VEGF/VEGFR lead to an enhanced antigen-presenting capacity of DCs. In addition, studies also found that these drugs inhibit the production of Tregs, TAMs and MDSCs at tumor sites, and negatively regulate the expression of immunosuppressive cytokines such as transforming growth factor-beta and interleukin-10[66].Therefore, blocking VEGF/VEGFR reprograms the immunosuppressive TME[67]. At the same time, the combination of PD-1/PD-L1 antibody can further enhance the antitumor activity of T cells. First, by reversing the VEGF-mediated suppression of DCs maturation resulting in efficient priming and activation of T cells[67,68]; second, by normalizing tumor vasculature and promoting efficient T cell infiltration into tumors[69]; and third, VEGF/VEGFR inhibitors inhibit the activity of MDSCs, Tregs,and TAMs, leading to the reprogramming of the immunosuppressive microenvironment to immune activation[61]. Finally, PD-1/PD-L1 inhibitors enhance the ability of T cells to attack tumor cells. These four aspects can lead to effective antitumor immunity and tumor growth inhibition. As described above,the use of molecularly targeted drugs against VEGF/VEGFR reactivates the aberrant immunosuppressive TME caused by VEGF, and finally allows the tumor cells to be effectively attacked[60,62]. A recent study of T+A therapy showed that the improved outcome of the combination of bevacizumab and atezolizumab compared with atezolizumab alone was mainly related to higher Tregs expression,suggesting that bevacizumab inhibits VEGF-enhanced antitumor immunity mainly related to inhibiting the function of Tregs[70]. Notably, previous studies have shown that anti-PD-1 therapy can increase tumor blood perfusion by normalizing blood vessels in breast and colorectal cancer models, which is closely related to its antitumor efficacy[71]. These studies form the rationale for the combination of VEGF/VEGFR inhibitors and PD-1/PD-L1 inhibitors.

    Table 2 Phase III clinical trials of combinations of anti-angiogenic inhibitors and immune checkpoint inhibitors in hepatocellular carcinoma

    Figure 1 Vascular endothelial growth factor promotes the formation of an immune suppressive microenvironment. VEGF: Vascular endothelial growth factor; DCs: Dendritic cells; MDSCs: Myeloid-derived suppressor cells; TAMs: Tumor-associated macrophages; Tregs: Regulatory T cells.

    Biomarkers to assess the response of targeted immunotherapy

    A major factor limiting the benefit of angiogenesis and immune checkpoint dual blockade for HCC is the lack of biomarkers to predict patients who can benefit from treatment. PD-L1 expression in tumor specimens was not associated with prognosis in HCC patients treated with nivolumab[48]. This study demonstrated that further comprehensive tumor and stromal immune scores, or tumor gene signatures should be explored. A recent study showed that pre-existing immunity (high expression of CD274, Teffector signature and intra-tumoral CD8+ T cell density) was positively associated with better clinical outcomes with the T+A combination and reduced clinical benefit was associated with a high Treg to effector T cell (Teff) ratio and expression of oncofetal genes (GPC3, AFP)[70]. Hatanakaet al[72] reported that C-reactive protein and AFP could be useful for predicting therapeutic outcomes and treatmentrelated AEs in HCC patients treated with the T+A combination. These results indicate that the clinical studies of bevacizumab combined with atezolizumab, lenvatinib combined with pembrolizumab,cabozantinib combined with atezolizumab and other combination therapies are a valuable platform for the analysis of other potential biomarkers of response to targeted immunotherapy and offer several new possibilities for identifying subpopulations of patients who benefit from these treatments. In several cancers, tumor mutational burden (TMB) and microsatellite instability (MSI) are associated with longer OS after ICB therapy. Considering the low frequency of TMB and MSI in HCC, their predictive applications in HCC are limited. However, it is worth noting that studies have shown that HCC with high TMB and low MSI responded to nivolumab for more than 2 years[73]. Thus, much more research is needed to determine the biomarkers of targeted immunotherapy in HCC.

    CONCLUSION

    The global disease burden of HCC is increasing year by year. According to statistics, the annual incidence of HCC may exceed 1 million cases in the near future, and most patients are in advanced stages at diagnosis. Currently, only reasonable systemic treatment can effectively delay the progression of HCC. This article describes the characteristics and treatment strategies of abnormal angiogenesis in HCC, and briefly reviews the immunotherapy of HCC. The strategy and rationality of angiogenesis and immune checkpoint dual blockade are further discussed. Among these combinatorial strategies, the success of the IMBrave150 clinical trial demonstrated that bevacizumab altered the tumor immune microenvironment, enabling greater responses to ICB, successfully transforming the immunosuppressive TME to an immune-activated microenvironment. Therefore, the efficacy achieved by the combination of anti-PD-1/PD-L1 antibody and VEGF/VEGFR inhibitor may be due to normalization of the TME. In addition to the combination of atezolizumab and bevacizumab, other combination therapies targeting the same mechanism have also received attention. While the clinical development of VEGF/VEGFR-targeted drugs is due to their anti-angiogenesis inhibitory effects, the potential of this class of drugs is as immunomodulators in combination with immunotherapy.

    In the post-sorafenib era of advanced HCC treatment, a great number of combination therapies are being studied. However, one of the biggest challenges with combination therapy is the discovery of predictive biomarkers to accurately identify patients most likely to respond to treatment. In the study of HCC, anti-angiogenesis therapy has been used for more than a decade and ICB has been approved for several years, but these two therapies still lack convincing biomarkers. Therefore, for combination therapy, a better understanding of the mechanism of synergistic therapeutic effect and the discovery of predictive biomarkers will help to design more precise treatment regimens.

    FOOTNOTES

    Author contributions:Li SQ, Yang Y and Ye LS carried out the research for the manuscript and edited all drafts of the paper.

    Supported byGuangdong Basic and Applied Basic Research Foundation, No. 2019A1515110654; the National Natural Science Foundation of China, No. 82103448; and China Organ Transplantation Development Foundation, No. YZLC-2021-003.

    Conflict-of-interest statement:All the authors report no relevant conflicts of interest for this article.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:China

    ORCID number:Yang Yang 0000-0003-4981-4745; Lin-Sen Ye 0000-0001-9632-1949.

    S-Editor:Wang JJ

    L-Editor:A

    P-Editor:Wang JJ

    亚洲专区中文字幕在线| 日日干狠狠操夜夜爽| 国内精品久久久久久久电影| 黄色 视频免费看| 99精品久久久久人妻精品| 成人国产综合亚洲| 可以在线观看的亚洲视频| 欧美午夜高清在线| 啦啦啦韩国在线观看视频| 无人区码免费观看不卡| 90打野战视频偷拍视频| 黄片小视频在线播放| 无遮挡黄片免费观看| ponron亚洲| 又紧又爽又黄一区二区| 免费在线观看视频国产中文字幕亚洲| 国产av麻豆久久久久久久| 久久久精品大字幕| 蜜桃久久精品国产亚洲av| 最新在线观看一区二区三区| 国产麻豆成人av免费视频| 国产熟女午夜一区二区三区| 青草久久国产| 久久精品91无色码中文字幕| cao死你这个sao货| 最近视频中文字幕2019在线8| 欧美黄色片欧美黄色片| 97人妻精品一区二区三区麻豆| 在线观看免费视频日本深夜| 一二三四在线观看免费中文在| 超碰成人久久| 黑人操中国人逼视频| 看片在线看免费视频| 国产欧美日韩一区二区精品| 成人手机av| cao死你这个sao货| 欧美日韩乱码在线| 久久中文字幕人妻熟女| 欧美一区二区国产精品久久精品 | 午夜影院日韩av| av免费在线观看网站| 777久久人妻少妇嫩草av网站| 国产精品国产高清国产av| 亚洲午夜理论影院| 丁香六月欧美| 伦理电影免费视频| 美女扒开内裤让男人捅视频| 色综合欧美亚洲国产小说| 精品无人区乱码1区二区| 精品欧美国产一区二区三| 免费看十八禁软件| 免费人成视频x8x8入口观看| 亚洲aⅴ乱码一区二区在线播放 | 人人妻人人看人人澡| 精品国产乱子伦一区二区三区| 亚洲av成人精品一区久久| 国产精品一区二区免费欧美| 一本精品99久久精品77| 在线播放国产精品三级| 法律面前人人平等表现在哪些方面| 欧美一级毛片孕妇| 99久久综合精品五月天人人| 久久久精品国产亚洲av高清涩受| 欧美一级毛片孕妇| 很黄的视频免费| 欧美乱妇无乱码| 日韩有码中文字幕| 在线观看免费午夜福利视频| 好男人在线观看高清免费视频| 成人手机av| 欧美乱妇无乱码| 午夜精品在线福利| 亚洲一卡2卡3卡4卡5卡精品中文| 1024手机看黄色片| 精品熟女少妇八av免费久了| 亚洲成av人片免费观看| 国产av又大| 国产亚洲av嫩草精品影院| 男人的好看免费观看在线视频 | 国产伦一二天堂av在线观看| 又黄又爽又免费观看的视频| 欧美不卡视频在线免费观看 | 久久人妻福利社区极品人妻图片| av在线天堂中文字幕| 国产伦人伦偷精品视频| 亚洲七黄色美女视频| 51午夜福利影视在线观看| 51午夜福利影视在线观看| 亚洲国产精品成人综合色| 久久亚洲真实| 色精品久久人妻99蜜桃| 嫁个100分男人电影在线观看| 桃红色精品国产亚洲av| 麻豆成人午夜福利视频| 一进一出抽搐动态| 无人区码免费观看不卡| 国产区一区二久久| 午夜福利成人在线免费观看| 国产人伦9x9x在线观看| 欧美久久黑人一区二区| 丁香六月欧美| 国产伦一二天堂av在线观看| 亚洲午夜精品一区,二区,三区| 中文亚洲av片在线观看爽| 全区人妻精品视频| 少妇粗大呻吟视频| 亚洲精品在线观看二区| 神马国产精品三级电影在线观看 | 给我免费播放毛片高清在线观看| 亚洲精品久久国产高清桃花| 亚洲一卡2卡3卡4卡5卡精品中文| 99热6这里只有精品| 两人在一起打扑克的视频| 欧美3d第一页| 最新在线观看一区二区三区| 久久伊人香网站| 精品久久久久久久久久久久久| 亚洲天堂国产精品一区在线| 夜夜躁狠狠躁天天躁| 中文字幕av在线有码专区| 日韩欧美在线乱码| 国产成+人综合+亚洲专区| 一二三四在线观看免费中文在| 久久香蕉精品热| 日本黄色视频三级网站网址| 老熟妇仑乱视频hdxx| 村上凉子中文字幕在线| 亚洲成人精品中文字幕电影| 国产一区在线观看成人免费| 午夜福利在线在线| 三级国产精品欧美在线观看 | 国产午夜福利久久久久久| 不卡一级毛片| 日韩免费av在线播放| 99国产极品粉嫩在线观看| 一级a爱片免费观看的视频| 久久精品国产亚洲av香蕉五月| 99国产极品粉嫩在线观看| 五月伊人婷婷丁香| 亚洲成人国产一区在线观看| 国产欧美日韩精品亚洲av| 嫩草影院精品99| 日日干狠狠操夜夜爽| 这个男人来自地球电影免费观看| 成人av在线播放网站| 最新在线观看一区二区三区| 欧美另类亚洲清纯唯美| 级片在线观看| 日日爽夜夜爽网站| 亚洲最大成人中文| 全区人妻精品视频| 亚洲美女黄片视频| 在线永久观看黄色视频| 岛国视频午夜一区免费看| 九九热线精品视视频播放| 亚洲国产精品成人综合色| 欧美人与性动交α欧美精品济南到| 免费看日本二区| 免费观看精品视频网站| 一区二区三区国产精品乱码| 国产精品免费视频内射| 夜夜看夜夜爽夜夜摸| 又粗又爽又猛毛片免费看| 国产蜜桃级精品一区二区三区| 欧美成人性av电影在线观看| 中亚洲国语对白在线视频| 亚洲欧美日韩高清专用| 成人av在线播放网站| 成人亚洲精品av一区二区| xxx96com| 熟妇人妻久久中文字幕3abv| 亚洲中文字幕日韩| 91字幕亚洲| 午夜免费观看网址| 久久久国产精品麻豆| 国产精品久久视频播放| 精品无人区乱码1区二区| 国产成人啪精品午夜网站| 男男h啪啪无遮挡| 小说图片视频综合网站| 久久久久久人人人人人| 亚洲自拍偷在线| 亚洲,欧美精品.| 免费观看人在逋| 青草久久国产| 熟女少妇亚洲综合色aaa.| 91老司机精品| www日本在线高清视频| 精品国产亚洲在线| 亚洲国产精品999在线| 中文字幕人妻丝袜一区二区| 在线观看美女被高潮喷水网站 | 日韩欧美一区二区三区在线观看| 中文字幕熟女人妻在线| 桃红色精品国产亚洲av| 可以免费在线观看a视频的电影网站| 免费一级毛片在线播放高清视频| 欧美精品啪啪一区二区三区| 精品少妇一区二区三区视频日本电影| 国产精品综合久久久久久久免费| 久久精品aⅴ一区二区三区四区| 欧美日韩中文字幕国产精品一区二区三区| 成在线人永久免费视频| а√天堂www在线а√下载| 禁无遮挡网站| 亚洲成a人片在线一区二区| 欧美久久黑人一区二区| 搞女人的毛片| 久热爱精品视频在线9| av天堂在线播放| 国产精品av视频在线免费观看| 国产亚洲欧美在线一区二区| 欧美在线一区亚洲| 女警被强在线播放| 色尼玛亚洲综合影院| 男男h啪啪无遮挡| 亚洲精品一卡2卡三卡4卡5卡| 欧美日本亚洲视频在线播放| 精品乱码久久久久久99久播| 日本免费a在线| 黄片大片在线免费观看| 免费在线观看亚洲国产| xxx96com| 女人爽到高潮嗷嗷叫在线视频| 亚洲色图av天堂| 日韩免费av在线播放| 久久99热这里只有精品18| 久久久国产精品麻豆| 亚洲国产欧美一区二区综合| 三级毛片av免费| 级片在线观看| 欧美乱色亚洲激情| 日本黄大片高清| 国产在线观看jvid| 国产欧美日韩精品亚洲av| 狠狠狠狠99中文字幕| 国产成人aa在线观看| 久久久久久久午夜电影| av视频在线观看入口| 国产麻豆成人av免费视频| 天堂影院成人在线观看| 在线观看舔阴道视频| 亚洲 欧美 日韩 在线 免费| 男人舔女人下体高潮全视频| 亚洲人成77777在线视频| 桃红色精品国产亚洲av| 日韩欧美国产在线观看| 国产免费男女视频| 此物有八面人人有两片| 深夜精品福利| 久久亚洲真实| 两人在一起打扑克的视频| 国产99久久九九免费精品| 亚洲中文字幕日韩| 久久亚洲精品不卡| 亚洲狠狠婷婷综合久久图片| 日韩大码丰满熟妇| 精品欧美一区二区三区在线| 精品久久久久久久人妻蜜臀av| 午夜两性在线视频| 少妇人妻一区二区三区视频| 国产一区二区激情短视频| 丝袜人妻中文字幕| 久久久国产成人精品二区| 欧美最黄视频在线播放免费| 亚洲人成网站在线播放欧美日韩| 一区福利在线观看| 90打野战视频偷拍视频| a级毛片a级免费在线| 真人一进一出gif抽搐免费| 亚洲avbb在线观看| 一级毛片女人18水好多| 国产成人精品久久二区二区免费| 国内精品一区二区在线观看| 岛国在线观看网站| 日韩成人在线观看一区二区三区| 19禁男女啪啪无遮挡网站| 国产成人aa在线观看| 黑人欧美特级aaaaaa片| 少妇熟女aⅴ在线视频| 神马国产精品三级电影在线观看 | 欧美3d第一页| 国产av麻豆久久久久久久| 精品国产亚洲在线| 欧美黄色片欧美黄色片| 亚洲精品中文字幕一二三四区| 久久久国产成人免费| 啦啦啦观看免费观看视频高清| 三级男女做爰猛烈吃奶摸视频| 一a级毛片在线观看| 久久中文字幕人妻熟女| 精品一区二区三区四区五区乱码| 人妻丰满熟妇av一区二区三区| 日韩精品中文字幕看吧| 午夜福利18| 俄罗斯特黄特色一大片| 免费在线观看亚洲国产| 在线观看舔阴道视频| 成人国产一区最新在线观看| 19禁男女啪啪无遮挡网站| 久久久国产成人免费| 99精品在免费线老司机午夜| 成人特级黄色片久久久久久久| 久久精品aⅴ一区二区三区四区| 欧美在线一区亚洲| 亚洲成a人片在线一区二区| 精品高清国产在线一区| ponron亚洲| 哪里可以看免费的av片| 亚洲精品久久国产高清桃花| 欧美极品一区二区三区四区| 国产亚洲精品一区二区www| www.自偷自拍.com| 久久精品国产清高在天天线| 国产精品久久视频播放| 久久伊人香网站| 亚洲av五月六月丁香网| 亚洲成人精品中文字幕电影| 黄色视频,在线免费观看| 桃色一区二区三区在线观看| 欧美高清成人免费视频www| 亚洲精品一区av在线观看| 国内毛片毛片毛片毛片毛片| 国产69精品久久久久777片 | 国产av一区在线观看免费| 亚洲精品一卡2卡三卡4卡5卡| 久久精品夜夜夜夜夜久久蜜豆 | 1024手机看黄色片| 国产成人av激情在线播放| 三级国产精品欧美在线观看 | 亚洲激情在线av| 免费人成视频x8x8入口观看| 又爽又黄无遮挡网站| 欧美性长视频在线观看| 无遮挡黄片免费观看| 91av网站免费观看| 亚洲第一欧美日韩一区二区三区| 少妇熟女aⅴ在线视频| 男人舔女人下体高潮全视频| 久久精品国产亚洲av高清一级| svipshipincom国产片| av免费在线观看网站| 18禁国产床啪视频网站| 在线观看午夜福利视频| 国产又黄又爽又无遮挡在线| 日本成人三级电影网站| 99热只有精品国产| 国产熟女午夜一区二区三区| xxx96com| 欧美一区二区精品小视频在线| 国产精品日韩av在线免费观看| tocl精华| 亚洲av成人一区二区三| 国产野战对白在线观看| 黄频高清免费视频| 99久久综合精品五月天人人| 激情在线观看视频在线高清| 国产不卡一卡二| 日韩大码丰满熟妇| 国产主播在线观看一区二区| 一本久久中文字幕| 亚洲国产日韩欧美精品在线观看 | 精品久久久久久久久久久久久| 国产精品一区二区精品视频观看| 亚洲激情在线av| 好男人在线观看高清免费视频| 波多野结衣巨乳人妻| 色在线成人网| av视频在线观看入口| 日韩欧美国产在线观看| 国产精品久久久久久久电影 | 少妇的丰满在线观看| 国产精品一区二区三区四区免费观看 | 99久久无色码亚洲精品果冻| 亚洲欧美精品综合久久99| 亚洲自偷自拍图片 自拍| 18禁黄网站禁片免费观看直播| 99久久无色码亚洲精品果冻| 日本一本二区三区精品| 国产高清视频在线播放一区| 亚洲性夜色夜夜综合| 一卡2卡三卡四卡精品乱码亚洲| 黑人巨大精品欧美一区二区mp4| 他把我摸到了高潮在线观看| 真人一进一出gif抽搐免费| 男男h啪啪无遮挡| 男女午夜视频在线观看| 亚洲国产精品成人综合色| 久久伊人香网站| 亚洲精品在线美女| 淫秽高清视频在线观看| 久久久久性生活片| 国产黄片美女视频| 欧美黄色片欧美黄色片| 久99久视频精品免费| 无限看片的www在线观看| 男女下面进入的视频免费午夜| 可以在线观看的亚洲视频| 亚洲一区二区三区不卡视频| 黄色女人牲交| 给我免费播放毛片高清在线观看| 免费观看精品视频网站| 老司机靠b影院| 国产精品精品国产色婷婷| 老司机福利观看| 黄色成人免费大全| 亚洲国产欧洲综合997久久,| 亚洲人与动物交配视频| 欧美 亚洲 国产 日韩一| 99精品欧美一区二区三区四区| 国产成人aa在线观看| 欧美日韩瑟瑟在线播放| 亚洲av美国av| 国产精品美女特级片免费视频播放器 | 亚洲av电影在线进入| 久久久水蜜桃国产精品网| 美女免费视频网站| av天堂在线播放| 国产亚洲av高清不卡| 亚洲av五月六月丁香网| 99热这里只有精品一区 | 男人舔奶头视频| 成在线人永久免费视频| 国内久久婷婷六月综合欲色啪| 久久婷婷成人综合色麻豆| 黄色视频,在线免费观看| 在线播放国产精品三级| 日韩欧美国产一区二区入口| 亚洲国产精品成人综合色| 可以在线观看毛片的网站| 成人三级黄色视频| 给我免费播放毛片高清在线观看| 免费在线观看视频国产中文字幕亚洲| 久久99热这里只有精品18| 在线观看日韩欧美| 两性午夜刺激爽爽歪歪视频在线观看 | 变态另类丝袜制服| 又爽又黄无遮挡网站| 国产99白浆流出| 欧美成人性av电影在线观看| 国产精品久久久久久精品电影| 床上黄色一级片| 成人三级做爰电影| 日本黄大片高清| 搡老妇女老女人老熟妇| 久久人妻av系列| 人人妻人人澡欧美一区二区| 久久久久九九精品影院| 国产亚洲精品一区二区www| 美女黄网站色视频| 成人国语在线视频| 不卡一级毛片| 一夜夜www| 看免费av毛片| 国产高清激情床上av| 无人区码免费观看不卡| 国产乱人伦免费视频| 国产精品精品国产色婷婷| 国产精品一区二区免费欧美| 亚洲成人中文字幕在线播放| 亚洲一卡2卡3卡4卡5卡精品中文| 欧美 亚洲 国产 日韩一| АⅤ资源中文在线天堂| 人妻久久中文字幕网| 精品电影一区二区在线| 男女之事视频高清在线观看| 丁香六月欧美| 亚洲美女视频黄频| 一夜夜www| 国产精品一区二区免费欧美| 美女大奶头视频| 亚洲成av人片免费观看| www日本在线高清视频| 亚洲国产欧洲综合997久久,| 99久久综合精品五月天人人| 亚洲全国av大片| 中国美女看黄片| 超碰成人久久| 国产亚洲欧美在线一区二区| 午夜成年电影在线免费观看| 精品电影一区二区在线| 久久精品91无色码中文字幕| 亚洲一区二区三区不卡视频| 亚洲成人国产一区在线观看| 国产视频内射| 午夜两性在线视频| 在线观看美女被高潮喷水网站 | 麻豆av在线久日| 成人一区二区视频在线观看| 18禁黄网站禁片免费观看直播| 欧美日韩福利视频一区二区| av福利片在线观看| av有码第一页| 观看免费一级毛片| 日韩精品免费视频一区二区三区| 久久性视频一级片| 成人高潮视频无遮挡免费网站| 国产av不卡久久| 丰满人妻熟妇乱又伦精品不卡| 女人高潮潮喷娇喘18禁视频| 亚洲色图 男人天堂 中文字幕| 变态另类成人亚洲欧美熟女| 狠狠狠狠99中文字幕| 窝窝影院91人妻| 色综合亚洲欧美另类图片| 特大巨黑吊av在线直播| 成人国产一区最新在线观看| 精品欧美国产一区二区三| 麻豆成人av在线观看| 母亲3免费完整高清在线观看| 色老头精品视频在线观看| 欧美性猛交黑人性爽| 九色国产91popny在线| 男女下面进入的视频免费午夜| aaaaa片日本免费| 成人av一区二区三区在线看| 日韩高清综合在线| 国产黄片美女视频| 丝袜美腿诱惑在线| 黄色毛片三级朝国网站| 国产私拍福利视频在线观看| 欧美一级毛片孕妇| 国产一区在线观看成人免费| av片东京热男人的天堂| 亚洲精品中文字幕在线视频| 免费看十八禁软件| 精品福利观看| 99国产精品一区二区蜜桃av| 亚洲成av人片在线播放无| 亚洲精品国产精品久久久不卡| 可以在线观看毛片的网站| 天堂√8在线中文| 成人精品一区二区免费| 国产一区二区三区在线臀色熟女| 亚洲成av人片在线播放无| 久久精品综合一区二区三区| 男女那种视频在线观看| 亚洲美女视频黄频| 色av中文字幕| 18禁黄网站禁片免费观看直播| 国产视频内射| 好男人电影高清在线观看| av福利片在线| 日本黄色视频三级网站网址| 色精品久久人妻99蜜桃| 亚洲一区中文字幕在线| 99国产综合亚洲精品| 久久久久久久久中文| АⅤ资源中文在线天堂| 淫妇啪啪啪对白视频| 日韩欧美三级三区| 精品久久久久久成人av| 国产在线观看jvid| 精品一区二区三区四区五区乱码| ponron亚洲| 久9热在线精品视频| 亚洲精品中文字幕在线视频| 国产成人精品久久二区二区91| 好看av亚洲va欧美ⅴa在| 亚洲狠狠婷婷综合久久图片| 久久 成人 亚洲| 国产三级黄色录像| 99精品在免费线老司机午夜| 天堂√8在线中文| 制服人妻中文乱码| 一区福利在线观看| 精品日产1卡2卡| 人人妻,人人澡人人爽秒播| 国产精品美女特级片免费视频播放器 | 桃红色精品国产亚洲av| 国产亚洲精品久久久久久毛片| 最近最新免费中文字幕在线| 亚洲欧美精品综合一区二区三区| 岛国在线免费视频观看| 欧美 亚洲 国产 日韩一| 精品免费久久久久久久清纯| 国产伦一二天堂av在线观看| 黄色视频,在线免费观看| 99久久99久久久精品蜜桃| 九九热线精品视视频播放| 日韩欧美在线乱码| 成在线人永久免费视频| 欧美乱码精品一区二区三区| 日韩欧美免费精品| 搞女人的毛片| 性色av乱码一区二区三区2| 欧美精品啪啪一区二区三区| 久久人妻福利社区极品人妻图片| 国产成+人综合+亚洲专区| 少妇裸体淫交视频免费看高清 | 国产av在哪里看| 久久久国产成人精品二区| 97人妻精品一区二区三区麻豆| 精品日产1卡2卡| 亚洲片人在线观看| 午夜久久久久精精品| 深夜精品福利| 欧美最黄视频在线播放免费| 欧美一区二区国产精品久久精品 | 日韩免费av在线播放| 日本一区二区免费在线视频| www.自偷自拍.com| 97超级碰碰碰精品色视频在线观看| 日本五十路高清| 精品一区二区三区四区五区乱码| 亚洲精品一区av在线观看| 最新在线观看一区二区三区| 久久久国产欧美日韩av| 亚洲免费av在线视频| 国产精品久久久av美女十八| 熟女少妇亚洲综合色aaa.| 国产高清激情床上av| 久久午夜综合久久蜜桃| 国产黄a三级三级三级人| 一级毛片高清免费大全|